Trial Profile
AN OPEN LABELLED EFFICACY AND TOLERABILITY STUDY OF NOVEL BETA-1- BLOCKER , NEBIVOLOL, ON HYPERTENSION WITH SPECIAL REFERENCE TO ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS.
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 26 Mar 2012 New trial record